Arcutis Biotherapeutics, Inc.
ARQT
$12.59
-$0.85-6.32%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 166.54M | 110.71M | 74.06M | 47.97M | 29.19M |
| Total Other Revenue | 30.00M | 28.00M | 58.00M | 58.42M | 30.42M |
| Total Revenue | 196.54M | 138.71M | 132.06M | 106.39M | 59.61M |
| Cost of Revenue | 19.13M | 14.47M | 10.15M | 7.46M | 4.99M |
| Gross Profit | 177.41M | 124.24M | 121.91M | 98.93M | 54.62M |
| SG&A Expenses | 229.39M | 220.46M | 209.24M | 197.02M | 185.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 324.94M | 320.64M | 311.83M | 302.85M | 300.71M |
| Operating Income | -128.40M | -181.93M | -179.77M | -196.46M | -241.10M |
| Income Before Tax | -139.39M | -195.19M | -195.39M | -214.05M | -259.09M |
| Income Tax Expenses | 647.00K | 349.00K | 3.37M | 3.37M | 3.05M |
| Earnings from Continuing Operations | -140.04 | -195.54 | -198.76 | -217.42 | -262.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -140.04M | -195.54M | -198.76M | -217.42M | -262.14M |
| EBIT | -128.40M | -181.93M | -179.77M | -196.46M | -241.10M |
| EBITDA | -125.80M | -179.41M | -178.29M | -194.94M | -239.58M |
| EPS Basic | -1.16 | -1.79 | -2.18 | -2.92 | -3.91 |
| Normalized Basic EPS | -0.72 | -1.12 | -1.33 | -1.79 | -2.41 |
| EPS Diluted | -1.16 | -1.79 | -2.18 | -2.92 | -3.91 |
| Normalized Diluted EPS | -0.72 | -1.12 | -1.33 | -1.79 | -2.41 |
| Average Basic Shares Outstanding | 483.75M | 451.41M | 388.84M | 326.79M | 276.91M |
| Average Diluted Shares Outstanding | 483.75M | 451.41M | 388.84M | 326.79M | 276.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
